Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin and Gemcitabine in HER2+ Metastatic Pancreatic Cancer
NCT00003797Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 1999
- Countries
- 1
- Sponsor
- Brown University
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- trastuzumab
- Conditions
- pancreatic cancer (PC)
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in pancreatic cancer (PC), sponsored by Brown University. Primary endpoints: Objective Response Rate, Overall Survival and 1 more. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Gemcitabine + Trastuzumab
Patients receive gemcitabine and trastuzumab combination therapy.
03
Who it enrols
Adults with metastatic pancreatic cancer overexpressing HER2/neu, measurable disease, adequate organ function, and LVEF >= 45%.
04
Endpoints
Primary
Objective Response Rate
Overall Survival
Toxic Effects
Beyond the preview
Go deeper on NCT00003797.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003797.